Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22710619 | 0.89 | BTK (0.64) | BTK | |
| SCHEMBL21044836 | 0.85 | BTK (0.76) | BTK | |
| SCHEMBL21044852 | 0.85 | BTK (0.76) | BTK | |
| SCHEMBL21044837 | 0.85 | BTK (0.76) | BTK | |
| SCHEMBL21044817 | 0.85 | BTK (0.53) | BTK | |
| SCHEMBL21044849 | 0.81 | BTK (0.53) | BTK | |
| SCHEMBL3117536 | 0.80 | EGFR (0.47) | BTK | |
| SCHEMBL29989719 | 0.80 | BTK (0.46) | BTK | |
| SCHEMBL28645870 | 0.80 | BTK (0.46) | BTK | |
| SCHEMBL15156494 | 0.77 | BTK (0.75) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023071973-A1 | FUSED BICYCLIC COMPOUND FOR INHIBITING ACTIVITY OF TYROSINE KINASE | SHENZHEN TARGETRX, INC. (CN) | 2023-05-04 | — | — | WO | disclosed |
| US-11186578-B2 | Substituted pyrrolo[3,2-d]pyrimidines and pyrazolo[4,3-d]pyrimidines as tyrosine kinase inhibitors | SHENZHEN TARGETRX, INC. (CN) | 2021-11-30 | — | — | US | disclosed |
| US-11186578-B2 | Substituted pyrrolo[3,2-d]pyrimidines and pyrazolo[4,3-d]pyrimidines as tyrosine kinase inhibitors | SHENZHEN TARGETRX, INC. (CN) | 2021-11-30 | — | — | US | disclosed |
| US-20210070758-A1 | FUSED BICYCLIC COMPOUND FOR INHIBITING ACTIVITY OF TYROSINE KINASE | Shenzhen TargetRx. Inc. (CN) | 2021-03-11 | — | — | US | disclosed |
| US-20210070758-A1 | FUSED BICYCLIC COMPOUND FOR INHIBITING ACTIVITY OF TYROSINE KINASE | Shenzhen TargetRx. Inc. (CN) | 2021-03-11 | — | — | US | disclosed |
| EP-3492471-B1 | FUSED BICYCLIC COMPOUND FOR INHIBITING ACTIVITY OF TYROSINE KINASE | SHENZHEN TARGETRX INC (CN) | 2020-12-02 | — | — | EP | disclosed |
| CN-109851620-B | Fused bicyclic compounds for inhibiting tyrosine kinase activity | 深圳市塔吉瑞生物医药有限公司 | 2020-08-07 | — | — | CN | disclosed |
| EP-3492471-A1 | FUSED BICYCLIC COMPOUND FOR INHIBITING ACTIVITY OF TYROSINE KINASE | Shenzhen Targetrx, Inc. (CN) | 2019-06-05 | — | — | EP | disclosed |
| EP-3492471-A1 | FUSED BICYCLIC COMPOUND FOR INHIBITING ACTIVITY OF TYROSINE KINASE | Shenzhen Targetrx, Inc. (CN) | 2019-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11186578-B2 | Substituted pyrrolo[3,2-d]pyrimidines and pyrazolo[4,3-d]pyrimidines as tyrosine kinase inhibitors | LCK, BTK, BRAF | BTK 2/4885 |
| US-20210070758-A1 | FUSED BICYCLIC COMPOUND FOR INHIBITING ACTIVITY OF TYROSINE KINASE | LCK, BTK, LYN | BTK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.